167 related articles for article (PubMed ID: 34318678)
1. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T; Pirovano G; Xiao G; Samuels Z; Roberts S; Viray T; Guru N; Zanzonico P; Gollub M; Pillarsetty NVK; Reiner T; Bargonetti J
Mol Pharm; 2021 Sep; 18(9):3418-3428. PubMed ID: 34318678
[TBL] [Abstract][Full Text] [Related]
2. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
3. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes
van de Ven AL; Tangutoori S; Baldwin P; Qiao J; Gharagouzloo C; Seitzer N; Clohessy JG; Makrigiorgos GM; Cormack R; Pandolfi PP; Sridhar S
Mol Cancer Ther; 2017 Jul; 16(7):1279-1289. PubMed ID: 28500233
[TBL] [Abstract][Full Text] [Related]
4. Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T
Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626
[TBL] [Abstract][Full Text] [Related]
5. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.
Zonneville J; Wang M; Alruwaili MM; Smith B; Melnick M; Eng KH; Melendy T; Park BH; Iyer R; Fountzilas C; Bakin AV
Commun Biol; 2021 Jul; 4(1):862. PubMed ID: 34253820
[TBL] [Abstract][Full Text] [Related]
6. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S; Zhou D; Mpoy C; Schenk E; Scott J; Arbeit JM; Xu J; Rogers BE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834491
[TBL] [Abstract][Full Text] [Related]
8. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
[TBL] [Abstract][Full Text] [Related]
9. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
[TBL] [Abstract][Full Text] [Related]
10. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
Jelinic P; Levine DA
Mol Cancer Ther; 2014 Jun; 13(6):1645-54. PubMed ID: 24694947
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR
Cancer Res; 2009 May; 69(9):3850-5. PubMed ID: 19383921
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
13. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
14. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Riad A; Gitto SB; Lee H; Winters HD; Martorano PM; Hsieh CJ; Xu K; Omran DK; Powell DJ; Mach RH; Makvandi M
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352773
[TBL] [Abstract][Full Text] [Related]
15. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
16. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
17. Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.
Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; Maretto M; Bassetti E; Caiazzo R; D'Orazi G; Cirone M
Exp Cell Res; 2021 Nov; 408(2):112879. PubMed ID: 34653407
[TBL] [Abstract][Full Text] [Related]
18. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
[Next] [New Search]
